Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
7496
Tickers With News
507
Showing Now
40
Top Ticker
TSLA
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.
Abbott Laboratories (NYSE:ABT) was among the stocks Jim Cramer talked about as he discussed the recent rally in several AI-related stocks. Cramer mentioned the company during the episode and stated: Now, let’s talk about some legendary growth companies and what’s happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and […]
ACTON, Mass., June 03, 2026--Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor
In its first earnings call, the newly independent diabetes tech firm said it was transforming its product portfolio, with plans that include a patch pump and an algorithm that doesn’t require meal announcements.
MiniMed (NASDAQ: MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.
Agreement builds on the companies' ongoing partnership to expand choice and simplify diabetes managementNORTHRIDGE, Calif., June 3, 2026 /CNW/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today
Abbott Laboratories currently has no change to its price target, with recent updates leaving existing estimates in place. In this article, you will see what this stable price target may mean for your view on the stock today and how to keep track of shifts as the analyst narrative evolves. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Abbott Laboratories. Do your thoughts align with the Bull or Bear Analysts? Perhaps you...
Robert Ford, Abbott Laboratories chairman and CEO, joins 'Squawk Box' to discuss the state of healthcare demand, the company's nutrition business, growth outlook, and more.
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
Earlier this week, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Abbott’s Cologuard and Cologuard Plus as preferred noninvasive options for average-risk adults aged 45 and older, to be used every three years. The guidelines, combined with real-world data showing Cologuard tests drove an estimated very large share of CRC screening participation growth between 2018 and 2021, underscore how Abbott’s screening platform and patient navigation...
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.
Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the systems are designed to continuously measure glucose and ketone levels every minute, providing real-time visibility into both glucose levels needed for daily diabetes management as well as rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency. This marks the fi
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
Abbott (NYSE:ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose‑ketone sensing technology for people with diabetes. Branded as Libre Duo and Libre Duo 10 Day, the
Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott Laboratories (NYSE:ABT) announced that the US Food and Drug Administration (FDA) and European regulators granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed […]
Abbott (NYSE:ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The
Abbott (NYSE: ABT) will present 11 abstracts featuring new evidence across the cancer care continuum at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago. The presentations showcase the breadth of Abbott's integrated cancer diagnostics portfolio and demonstrate how its tests support critical decision points—from identifying risk and detecting disease earlier to guiding treatment and monitoring for recurrence.
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q1 2026 investor letter for its “Large Cap Strategy”. A copy of the letter is available to download here. The Strategy declined 2.39% (net of fees), trailing the Russell 1000 Value Index’s 2.10%. The performance was positively affected by stock selection in industrials and consumer discretionary, along […]
If you are wondering whether Abbott Laboratories at around US$87.41 is a bargain or a value trap, it helps to step back and look at what the current price really implies. The stock has gained 3.5% over the past week, although it remains down 4.7% over the past month and has declined 29.6% year to date and 32.1% over the last year, which may have shifted how investors view its risk and potential reward. Recent coverage has focused on Abbott Laboratories as a large healthcare stock with a long...
Abbott Laboratories (NYSE:ABT) is expanding its presence in health tech with new diagnostics and wearable products, including the Lingo biomarker monitoring device. The company is also increasing R&D activity in cardiovascular diagnostics, aiming to broaden its role in earlier detection and ongoing monitoring of heart related conditions. These product moves come as attention on Abbott has recently centered on earnings, insider activity, and the Exact Sciences acquisition rather than its...
While ABT stock appears poised to reach the year’s halfway mark in ignominy, the options market is quietly signaling a possible recovery.
The global Paroxysmal Supraventricular Tachycardia (PSVT) market is set for significant growth, driven by advancements in diagnostics and treatment, and rising cardiovascular awareness. Key factors include a surge in cardiovascular diseases, especially in the aging population, and increased use of minimally invasive techniques like catheter ablation. Emerging economies present ample opportunities, supported by improving healthcare infrastructure and preventive healthcare focus. Challenges persis
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Abbott vs. Zimmer Biomet: surgical equipment stocks face diverging growth, acquisitions, and valuation shifts as investors weigh momentum and margins.
The Japan in vitro diagnostics market is ripe for growth due to the aging population's demand for chronic illness management, technological innovations like AI, point-of-care devices, and supportive government policies. Key opportunities exist in laboratory and point-of-care testing, with reagents dominating market share.Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Japan In Vitro Diagnostics Market: Distribution by Test Type, Type of Offering, Type of Technology, Therapeutic Area, End Users and
The wearables in pharma & biotech market is forecasted to grow from USD 3.98 billion in 2026 to USD 9.97 billion by 2031, at a CAGR of 20.2%. This rapid growth is fueled by advances in biosensor technology, miniaturization, and digitization, supported by strong internet connectivity worldwide. Programs like "All of Us" and RPM adoption are boosting wearables' role in research and healthcare. CGMs lead product segments due to robust clinical backing, while pharma and biotech companies were top en
The kernicterus market is experiencing growth, fueled by an increase in neonatal jaundice cases, particularly among preterm infants. Major drivers include advancements in neonatal screening protocols and the development of non-invasive diagnostic tools like transcutaneous bilirubinometers. Phototherapy innovations, including LED and IoT-enabled systems, enhance treatment efficiency and patient monitoring. North America and Europe lead the market with advanced care systems, while significant grow
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The global hepatic cirrhosis market is expanding rapidly, fueled by increasing liver disease cases, advanced treatment options, and improved healthcare infrastructure. Conditions like hepatitis, alcohol abuse, and metabolic dysfunction-associated steatotic liver disease (MASLD) are elevating cirrhosis prevalence, especially in regions with factors like high alcohol consumption. Innovative treatments, including antiviral drugs and antifibrotic agents, are gaining traction, though challenges such
In Q1 2026, Abbott Laboratories reported a modest earnings beat, closed its US$21.00 billion Exact Sciences acquisition to expand in cancer diagnostics, and outlined a new volume-led Nutrition strategy after a 6% sales decline, while continuing to face significant infant formula litigation and regulatory scrutiny. These developments have prompted analysts and commentators to reassess Abbott’s execution risks and diversification benefits, balancing dilution from the Exact Sciences deal...
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Abbott Laboratories (NYSE:ABT) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer highlighted it as one of the “greatest American companies,” as he said: …Let’s talk about some similarities that have now been popping up, okay? In 1999, we saw […]
ABT's Q1 beat was overshadowed by Exact Sciences dilution, legal risks and weak Diagnostics trends as shares hit a 52-week low.
The Australia regenerative medicine market offers significant opportunities in cellular therapies, tissue engineering, and aesthetic applications, driven by aging populations and chronic disease prevalence. Key growth is seen in oncological applications and hospital adoption, with strong government backing and technological advancements enhancing potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Australia Regenerative Medicine Market - Distribution by Type of Products, Type of Therapeutic
Abbott Laboratories is under fresh scrutiny as price targets are reset, with some analysts trimming their expectations and others keeping fair value estimates such as US$118.64 broadly intact. The more cautious tone in recent research, including cuts to targets and removal from a key US conviction list, sits alongside ongoing supportive views that still see room for upside versus analysts’ own fair value work. As you read on, you will see how to track these shifting targets and use the...
